Biopolym. Cell. 2021; 37(3):167-176.
Viruses and Cell
N-stearoylethanolamine - a new inhibitor of the hepatitis C virus reproduction
1Hula N. M., 1Chumak A. A., 1Berdyshev A. G., 1Kosiakova G. V., 1Goridko T. M., 1Meged’ O. F., 1Asmolkova V. S., 2Porva Yu. I., 2Rybalko S. L., 2Dyadun S. T., 2Starosyla D. B., 2Deryabin O. M.
  1. Palladin Institute of Biochemistry, NAS of Ukraine
    9, Leontovycha Str., Kyiv, Ukraine, 01601
  2. Gromashevsky L. V. Institute of Epidemiology and Infection Diseases, NAMS of Ukraine
    5, Amosova Str., Kyiv, Ukraine, 03038


Aim. The study of the effect of endogenous cannabimimetic compound – N-stearoylethanolamine (NSE) on the hepatitis C virus (HCV) reproduction. Methods. The model of the surrogate HCV is a bovine diarrhea virus; cell culture model is cells transfected with cDNA of the human HCV and molecular docking has been used. Results. In vitro studies showed that NSE effectively inhibited the reproduction of a surrogate HCV in both MDBK cells and transfected Jurkat cells. Molecular docking suggested that NSE can bind to the active centers of both NS3 serine protease and HCV NS5B-polymerase and has an inhibitory effect on their activity. Conclusions. The obtained data confirm that using NSE is promising for the development of antiviral drug to suppress the HCV activity.
Keywords: N-stearoylethanolamine, antiviral activity, hepatitis C virus, molecular docking


[1] Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med. 2001; 345(1):41-52.
[2] Danny JE, Delphi GMC, Tara LP, Laurien AR, Jayasree KI. Access to hepatitis C medicines. Bulletin of the World Health Organization. 2015; 93:799-805.
[3] Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetali-poproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J. Hepatol. 2001; 34(3):428-434.
[4] Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl. Acad. Sci USA. 2005; 102(7):2561-2566.
[5] Kim SS, Peng LF, Lin W, Choe WH, Sakamoto N, Kato N, Ikeda M, Schreiber SL, Chung RT. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology. 2007; 132(1):311-320.
[6] Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, Yarmush ML. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology. 2008; 47(5):1437-1445.
[7] Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 2008; 82(5):2120-2129.
[8] Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment - finding the right path. Nat. Rev. Drug Discov. 2007; 6(12):991-1000.
[9] Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Re-yor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer G.M, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Ed-lin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. Naturally occurring do-minant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008; 48(6):1769-1778.
[10] O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology. 2007; 45(4):895-898.
[11] Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, Konishi M, Iwasa M, Watanabe S, Adachi Y. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J. Viral Hepat. 2006; 13(7):441-448.
[12] Gula NM, Chumak AA, Rybalko SL, Dyadyn ST, Asmolkova VS, Berdyshev AG, Kosyakova GV, Starosila DB, Benkovsky LK, Bashta YuM. Antiinfluenza effect of N-stearoylethanolamine. J. Nat. Acad. Med. Sci. of Ukraine. 2014; 20(4):393-401.
[13] Hula NM., Chumak AA., Mehed OF. Immunosuppressive characteristics of N-stearoylethanolamine a stable compound with cannabimimetic activity. Ukr. Biokhim. Zh. 2008; 80 (1): 57-67 (Article in Ukrainian).
[14] Rybalko SL, Porva Yu, Alekseenko IP, Diadiun ST, Zavelevych MP, Borovykov VM, Popova LA, Fedorchenko DB. Replication of hepatitis C virus in cell culture. Biopolymers and Cell. 2009; 25(1):44-49.
[15] Porva Yu, Rybalko SL, Palchykovs'ka LI, Atamanyuk VP. Study of antiviral activity of a new plant origin prepa-ration neoflazidum on a model of the hepatitis C virus. Biopolymers and Cell. 2015; 31(6):465-472.
[16] Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nature protocols. 2016; 11(5):905.
[17] Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry. 2010; 31(2):455-61.
[18] O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011; 3:33.
[19] Durantel D, Alotte C, Zoulim F. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr. Opin. In-vestig. Drugs. 2007; 8(2):125-129.
[20] Huang SY, Zou X. Advances and challenges in proteinligand docking. Int J Mol Sci. 2010; 11:3016-3034.
[21] Wei Y, Yang J, Kishore Sakharkar M, Wang X, Liu Q, Du J, Zhang JJ. Evaluating the inhibitory effect of eight compounds from Daphne papyracea against the NS3/4A protease of hepatitis C virus. Nat Prod Res. 2018; 17:1-4.
[22] Ahmed-Belkacem A, Guichou J-F, BrilletR. Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: a new mechanism for antiviral intervention. Nucl Acids Res. 2014;42(14): 9399-409.